Minimally invasive glaucoma surgery (MIGS) devices
Strategic Profile
Ivantis positioned itself in the high-growth MIGS segment of ophthalmology, targeting surgeons and patients seeking less invasive alternatives to traditional glaucoma procedures. The Hydrus Microstent technology was FDA-approved in August 2018 and represented a differentiated approach to surgical glaucoma management. The Alcon acquisition integrated Ivantis into a larger global ophthalmology portfolio, enabling broader market reach and patient access.
Cyborg Score Rationale
Company was acquired in January 2022 and is no longer independently operational as of July 2026. Historical evaluation not applicable.
Top Insights
Ivantis raised approximately $136–$166M across 7 funding rounds from prominent healthcare investors including New Enterprise Associates, Delphi Ventures, and RA Capital Management
The Hydrus Microstent is a clinically proven device approved by the FDA for use with cataract surgery and as a standalone procedure in international markets (UK, Canada, Australia, Singapore, Germany)
Company held 59 patents, demonstrating significant intellectual property in the MIGS and ophthalmic device space
Ivantis operated in the fastest-growing segment of the ophthalmology market, positioning it as a strategic asset for a global eye-care company like Alcon
Named Competitors
MIGS Platforms — Leading MIGS device manufacturer with multiple surgical solutions